HomeNDC LookupDrug shortages › Sodium Acetate Injection

Sodium Acetate Injection shortage

Sodium Acetate Injection is currently listed in shortage by the FDA. The FDA lists 15 affected products. The reported reason: Other. This page was last refreshed from FDA data on Sep 23, 2026.

Current ⚠ Supply risk: Low Endocrinology/Metabolism, Gastroenterolo... 15 products 5 manufacturers 3,885 days · 10.6 yr First posted Feb 3, 2016 Updated Sep 18, 2026
Here’s the bottom line

Sodium Acetate Injection has been on the FDA shortage list for over a year, though all five reporting manufacturers still show some supply available. Every strength currently has at least one source, and additional supply is also listed from Amneal Pharmaceuticals.

Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
15
Affected NDCs
5
Reporting manufacturers
5/5
Reporting mfrs supplying
9/9
Affected strengths supplied
0%
NDCs unavailable
3,885
Days in shortage
20,482
Medicaid Rx (2025)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 23, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Sodium Acetate Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
15 NDCs
Available 13 Limited 2
Affected strengths still supplied
Among manufacturers reporting this shortage
9/9 strengths
Sourceable 9
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
5/5 makers
With supply 5
✓ Other manufacturers not reporting a shortage
Still-marketed Sodium Acetate Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Amneal Pharmaceuticals Private Limited
Plus 1 alternative dosage form of Sodium Acetate.
See all other options & details →
Shortage timeline
  1. Sep 18, 2026
    Currently in shortage
    15 of 15 products affected.
  2. Sep 16, 2026
    FDA refreshed this shortage record
    4 products updated.
  3. Sep 15, 2026
    FDA refreshed this shortage record
    1 product updated.
  4. Sep 11, 2026
    FDA refreshed this shortage record
    2 products updated.
  5. Sep 9, 2026
    FDA refreshed this shortage record
    5 products updated.
  6. Aug 24, 2026
    FDA refreshed this shortage record
    1 product updated.
  7. Mar 23, 2016
    More presentations reported
    3 more products added to the shortage.
  8. Feb 3, 2016
    First reported to the FDA
    12 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
Current Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00) NDC 63323-0032-00 Available Check wholesalers for inventory
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
Current Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01) NDC 00641-6262-01 Available Additional lots will be available. Product will be made available as it is released.
Current Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01) NDC 00641-6261-01 Available Additional lots will be available. Product will be made available as it is released.
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 6 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
Current Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25) NDC 00409-3299-25 Available
Current Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05) NDC 00409-3299-05 Available
Current Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26) NDC 00409-3299-26 Available
Current Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25) NDC 00409-7299-25 Available
Current Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73) NDC 00409-7299-73 Available
Current Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06) NDC 00409-3299-06 Limited Availability Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay Other
Manufacturer: Milla Pharmaceuticals 📞 833-251-8463 4 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
Current Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10) NDC 71357-0008-10 Available
Current Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10) NDC 71357-0002-10 Available
Current Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10) NDC 71357-0007-10 Available
Current Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10) NDC 71357-0009-10 Limited Availability Estimated recovery: TBD Other
Manufacturer: Somerset Therapeutics, LLC 📞 732-554-1037 2 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
Current Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20) NDC 70069-0048-20 Available
Current Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25) NDC 70069-0047-25 Available

These rows are manufacturer reports to the FDA for Sodium Acetate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Sodium Acetate Injection? options further down this page.

Why is Sodium Acetate Injection in shortage?

There are two specific products in this shortage report that have limited availability. Hospira (a Pfizer company) is reporting a manufacturing delay — basically a hold-up at the factory — affecting their 200 mEq/100 mL (2 mEq/mL) sodium acetate injection. They expect their next delivery and recovery from that shortage around September 2026. Separately, Milla Pharmaceuticals has limited availability of their 400 mEq/100 mL (4 mEq/mL) product, and they haven't given a specific reason beyond "other" — with no estimated recovery date yet (listed as TBD).

It's worth knowing that several other strengths and package sizes from these same manufacturers — as well as products from Hikma, Somerset Therapeutics, Fresenius Kabi, and Hospira's other package sizes — are currently listed as available. So the shortage is really centered on those two specific products, not sodium acetate injection as a whole from every maker.

FDA reason code(s): Other

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Sodium Acetate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Sodium Acetate Injection?

Sodium Acetate Injection is currently on the FDA drug-shortage list, but supply overall remains steady. This product is given through an IV in a clinical setting, so any adjustments are handled by your care team rather than by you at home.

Every strength on this record still has an available source. That includes the 40 mEq/20 mL, 100 mEq/50 mL, 200 mEq/100 mL, and 400 mEq/100 mL (all 2 or 4 mEq/mL versions), as well as the 164 mg/mL and 4 mEq/100 mL products. No strength is completely without a source right now. A few items are tighter than others — the 400 mEq/100 mL is listed as limited with recovery still to be determined, and one 200 mEq/100 mL lot has an estimated recovery of September 2026 — but other makers still supply these sizes.

The FDA lists the reason simply as "Other," and all five manufacturers on this record are still reporting available supply. That is a reassuring sign.

Here is what I suggest:

  • Do not skip or change any dose on your own; your care team manages this medicine.
  • Ask your pharmacy to order your strength — they can check wholesalers and other manufacturers.
  • The same medicine is also made by Amneal (164 mg/mL); your pharmacy may be able to source it, though it may not be in local stock.

Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.

This is general, national information and may not match your local pharmacy's stock.

See “Where else can I get Sodium Acetate Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Sodium Acetate guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Sodium Acetate guide →

Where else can I get Sodium Acetate Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Sodium Acetate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Sodium Acetate SODIUM ACETATE ANHYDROUS 164 mg/mL Injection, Solution, Concentrate · Intravenous Amneal Pharmaceuticals Private Limited 80830-2436-02

Alternative dosage forms of Sodium Acetate

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 15 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Sodium Acetate 4 meq/100mLNDC 63323-0032-00 Fresenius 20 vials AP FDA listed
Sodium Acetate 400 meq/100mLNDC 71357-0009-10 MILLA 10 vials AP FDA listed
Sodium Acetate 164 mg/mLNDC 00409-3299-25 Hospira, 25 vials AP FDA listed
Sodium Acetate 164 mg/mLNDC 00641-6262-01 Hikma 1 vial AP FDA listed
Sodium Acetate 164 mg/mLNDC 00641-6263-10 Hikma 10 vials AP FDA listed
Sodium acetate anhydrous 164 mg/mLNDC 70069-0047-25 Somerset 25 vials AP FDA listed
Sodium acetate anhydrous 164 mg/mLNDC 70069-0048-20 Somerset 20 vials AP FDA listed
Sodium Acetate 164 mg/mLNDC 71357-0007-10 MILLA 10 vials AP FDA listed
Sodium Acetate 200 meq/100mLNDC 71357-0008-10 MILLA 10 vials AP FDA listed
Sodium Acetate 164 mg/mLNDC 80830-2436-02 Amneal 25 vials AP FDA listed
Sodium Acetate 164 mg/mLNDC 80830-2437-02 Amneal 10 vials AP FDA listed
Sodium Acetate 164 mg/mLNDC 00641-6261-01 Hikma 1 vial AP FDA listed
Sodium Acetate 164 mg/mLNDC 80830-2435-02 Amneal 25 bottles AP FDA listed
Sodium Acetate 3.28 g/20mLNDC 00409-7299-25 Hospira, 25 vials AP FDA listed
Sodium Acetate 164 mg/mLNDC 71357-0002-10 MILLA 10 vials AP FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Sodium Acetate Injection — that fall in the same broad treatment class (bicarbonate producing/containing agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 001206
GCN 02923
HICL code 000536
Ingredient (HICL) Sodium Acetate
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C0
Therapeutic class — intermediate (HIC2) Affect Fluid/Acid-Base Balance/Metabolic Systems
HIC3 code C0K
Therapeutic class — specific (HIC3) Bicarbonate Producing/Containing Agents
AHFS code 40:12.00.00
AHFS class Replacement Preparations
FDB label name SODIUM ACETATE 400 MEQ/100 ML
FDB brand name Sodium Acetate
Legend status F — Federal legend — prescription drug or device
GPI-1479050010002010
GPI classSodium Acetate
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Sodium Acetate Injection shortage FAQs

Is Sodium Acetate Injection in shortage?
Yes — the FDA currently lists Sodium Acetate Injection in shortage (status: “Current”, first reported Feb 3, 2016). 15 of 15 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Why is Sodium Acetate Injection in shortage?
The manufacturer-reported reason on file with the FDA: Other.
Which products are affected?
Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00) (NDC 63323-0032-00); Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01) (NDC 00641-6262-01); Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01) (NDC 00641-6261-01). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Sodium Acetate Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Sodium Acetate somewhere?
Other manufacturers (Amneal Pharmaceuticals Private Limited) still market it and have not reported a shortage. 1 alternative dosage form of Sodium Acetate is also listed. See “Where else can I get Sodium Acetate Injection?” above — stock still varies by pharmacy.
What should I do if I take Sodium Acetate Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Sodium Acetate Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages